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Influence of hematocrit on the measurement of lipoproteins
demonstrated by the example of lipoprotein(a).
Background. The measurement of many parameters of human
blood is usually performed in plasma or serum. Since lipoproteins
or apolipoproteins, for example, are found almost exclusively in
the plasma fraction after low-speed centrifugation, these param-
eters can be expected to be distributed in a different plasma
volume depending on the hematocrit value. Therefore, the mea-
sured plasma levels might be relatively too low or too high in
comparison to the whole blood concentrations in the case of
abnormal hematocrit levels. The aim of our experiments was to
evaluate the extent of differences between whole blood and
plasma concentrations, taking as an example lipoprotein(a)
[Lp(a)] in hemodialysis patients with documented decreased
hematocrit values.
Methods. Lp(a) was measured in plasma as well as whole blood
of 15 hemodialysis patients with low hematocrit values (0.29 6
0.02) in comparison to 11 control subjects (0.45 6 0.04).
Results. Plasma concentrations were 27% higher in patients
than in controls (19.7 vs. 15.5 mg/dl). The relative difference was
twice as high (59%) when measured in whole blood (13.5 vs. 8.5
mg/dl). Similar relative differences were observed when whole
blood concentrations of 125 hemodialysis patients and 256 con-
trols were calculated with the formula
[Lp(a)pasma p (12hematocrit)].
Conclusions. Our findings clearly demonstrate that he-
matocrit is a strong confounding variable of lipoprotein
measurement in epidemiological studies when concentra-
tions are measured in plasma, especially in cases of abnor-
mal hematocrit values. Furthermore, studies investigating
the longitudinal changes of lipoproteins should consider
potential hematocrit changes.
Lipoproteins and apolipoproteins are usually measured
in plasma or serum [1]. This is convenient and can be done
in frozen samples. Whole blood measurements are impos-
sible in many cases since especially colorimetric assays are
disturbed by high levels of bilirubin or hemoglobin. Han-
dling of whole blood samples using micropipettes or auto-
mated pipetting also often disturbs the measurement due to
pipette clogging. Despite the uncontested advantages of
measurement in plasma or serum, the possible influence of
abnormal hematocrit values in case-control studies and of
fluctuating hematocrit values in longitudinal studies re-
mains to be evaluated.
During recent years several studies described an associ-
ation between high lipoprotein(a) [Lp(a)] plasma concen-
trations and coronary heart disease [2, 3]. Patients with
renal disease have an increased risk for coronary heart
disease [4, 5] and high Lp(a) plasma concentrations [6–13;
reviewed in 4]. This patient group also suffers from renal
anemia with low hematocrit values. The aim of this study
was, therefore, to investigate the influence of hematocrit
values on the measurement of parameters distributed ex-
clusively in the plasma fraction after low-speed centrifuga-
tion. We attempted to illustrate this question by measuring
Lp(a) in hemodialysis patients. We demonstrate that Lp(a)
from the whole blood of hemodialysis patients is distrib-
uted in a higher plasma volume after centrifugation due to
the low hematocrit levels in these patients. Therefore, the
amount and possibly also the clinical relevance of Lp(a) in
these patients is underestimated in relative terms when
measured as plasma instead of whole blood concentration
(Fig. 1).
METHODS
Patients and controls
In a first step we measured Lp(a) in whole blood as well
as in the plasma of 15 hemodialysis patients with hemato-
crit values below 0.33 and 11 healthy control subjects to
investigate the effect of various hematocrit values on Lp(a)
concentrations. Additionally, the whole blood concentra-
tions of Lp(a) from 125 randomly selected hemodialysis
patients were calculated using the formula [Lp(a)plasma p
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(1 2 hematocrit)]. Whole blood as well as plasma concen-
trations of Lp(a) in these patients were compared with
those of 256 healthy control subjects.
Laboratory procedures
Nine milliliters of ethylenediaminetetraacetate (EDTA)
blood were withdrawn from 15 hemodialysis patients im-
mediately preceding the onset of dialysis therapy and from
11 controls. After blood withdrawal, 2 ml of whole blood
were stored in an ice bath, and the rest was centrifuged for
15 minutes at 1500 3 g at 4°C. Plasma and 1 ml of cells
were separated and stored in an ice bath.
Lp(a) was measured in plasma and whole blood by
ELISA exactly as previously described [14]. To determine
whether whole blood disturbs the measurement of Lp(a),
we added 50 ml of a plasma sample with a high Lp(a)
concentration to 150 ml whole blood from six individuals.
Lp(a) was then measured in the whole blood with and
without added plasma. In parallel, we also measured Lp(a)
in the plasma samples from the six individuals above, to
which plasma with high Lp(a) concentration had been
added. Furthermore, Lp(a) was measured in the cell frac-
tion after resuspending with 150 mM sodium chloride
solution in four out of the six subjects. Each sample was
diluted and analyzed in triplicate. With this method the
intraassay coefficient of variance was 2.5% for plasma and
2.4% for whole blood measurements.
Hematocrit values were determined with a Coulter
Counter T660 (Coulter Cooperation, Miami, USA).
Statistical calculations
The Spearman rank correlation coefficient was calcu-
lated between the measured whole blood concentrations
and those calculated with the formula [Lp(a)plasma p (1 2
hematocrit)]. The nonparametric Wilcoxon rank sum test
was used to compare the plasma as well as whole blood
concentrations of Lp(a) between 125 hemodialysis patients
and 256 controls.
RESULTS
In a first step we investigated whether measurement of
Lp(a) in whole blood samples is influenced by the presence
of blood cells. For this purpose, we added 50 ml plasma with
a high Lp(a) concentration to 150 ml whole blood and to
150 ml plasma of six control subjects. Then we measured
Lp(a) in plasma, whole blood, plasma 1 added plasma and
whole blood 1 added plasma. We found that the added
amount of Lp(a) was completely recovered in the whole
blood as well as in the plasma sample (Table 1). From this
experiment we concluded that measurement of Lp(a) in
whole blood was not disturbed by blood cells. Furthermore,
Lp(a) was also measured after low-speed centrifugation of
whole blood in the bottom fraction containing mainly cells.
Less than 5% of the values measured in plasma were
detected in the cell fraction, which demonstrates that Lp(a)
is distributed nearly exclusively in the plasma fraction after
centrifugation (Table 1).
Fig. 1. Schematic illustration of the effect of hematocrit level on the
measurement of a parameter (shown as black dots), which is homoge-
neously distributed in the plasma fraction after centrifugation. In the
event of a decreased hematocrit value, a markedly lower plasma concen-
tration will be measured compared to a subject with the same whole blood
concentration but normal hematocrit value.
Table 1. Influence of blood cells on the measurement of Lp(a)
(in mg/dl)
Subject
A B C D E F
Plasma 0.81 7.08 21.7 90.7 2.44 22.8
Whole blood 0.42 3.76 11.4 49.0 0.95 11.4
Added plasma (AP) 95.3 95.3 95.3 86.2 58.5 58.5
150 ml plasma 1 50 ml AP
Measured 22.7 29.0 40.6 86.3 18.4 32.7
Calculateda 24.4 29.1 40.1 89.6 16.5 31.7
150 ml whole blood 1 50 ml AP
Measured 23.3 26.2 30.8 57.4 14.7 24.9
Calculatedb 24.1 26.6 32.4 58.3 15.3 23.2
Cell fraction 0.02 0.2 0.7 3.5 ND ND
We added 50 ml plasma with a high Lp(a) concentration to 150 ml whole
blood and to 150 ml plasma of six control subjects (A-E). The added
amount of Lp(a) was completely recovered in the whole blood as well as
in the plasma sample. Abbreviations are: AP, added plasma; ND, not
determined.
a Calculated with the formula: ((150 p [plasma]) 1 (50 p [AP]))/200
b Calculated with the formula: ((150 p [whole blood]) 1 (50 p [AP]))/
200
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We then measured Lp(a) in plasma as well as whole blood
samples from 15 hemodialysis patients with low hematocrit
values (0.29 6 0.02) in comparison to 11 control subjects with
normal hematocrit (0.45 6 0.04). Lp(a) plasma concentra-
tions were 27% higher in patients than in controls (19.7 vs.
15.5 mg/dl). The absolute values of Lp(a) were markedly
lower when measured in whole blood of patients and controls
(13.5 vs. 8.5 mg/dl) since Lp(a) was then distributed in a larger
volume. The relative difference, however, was twice as high
(59%) when measured in whole blood (Fig. 2).
In addition, whole blood levels of Lp(a) were also
calculated with the formula [Lp(a)plasma p (1 2 hemato-
crit)]. Measured and calculated values correlated very well
(r 5 0.99; Fig. 3) with a mean relative difference of 4.4 6
5.6%. The measured mean concentration, however, was
slightly lower than the calculated one: 11.4 versus 11.7
mg/dl in the combined group of patients and controls. This
can be explained by the small amount of Lp(a) remaining in
the cell fraction due to the “mild” low-speed centrifugation
procedure.
Finally, we calculated the whole blood values of Lp(a) in
a group of 125 hemodialysis patients with a mean hemat-
ocrit value of 0.34 6 0.07. Similar to an earlier study [7], in
hemodialysis patients we observed 38% higher Lp(a)
plasma concentrations than in the control group (25.4 6
28.5 vs. 18.4 6 22.8 mg/dl). The calculated relative differ-
ence in the whole blood concentrations of the same two
groups, however, was 70% (16.8 6 19.6 vs. 9.9 6 12.4
mg/dl), and therefore nearly twice as high as the relative
difference for measured plasma concentrations.
DISCUSSION
In this investigation we describe a strong influence of the
hematocrit value on lipoprotein concentrations measured
in plasma, using Lp(a) as an example. We clearly demon-
strate that subjects who have identical plasma concentra-
tions of Lp(a) have markedly different whole blood con-
centrations in the case of different hematocrit values. This
can be explained by the nearly exclusive distribution of
Lp(a) and other lipoproteins in the plasma fraction after
low-speed centrifugation. In patients with a low hematocrit
level, lipoproteins are found in a larger plasma fraction
after centrifugation, and therefore show a lower plasma
concentration when compared to a subject with normal
hematocrit and the same content of Lp(a) in whole blood
(Fig. 1). Unfortunately, no study is available, to our knowl-
edge, which systematically investigated whether the whole
blood or the plasma concentrations of lipoproteins are
Fig. 2. Effect of a decreased hematocrit value
on the plasma and whole blood concentration
of Lp(a) in 15 hemodialysis patients (f) in
comparison to 11 control subjects (u) with
normal hematocrit values. The relative increase
of Lp(a) in patients compared to controls was
markedly more pronounced when measured in
whole blood (159%) instead of plasma
(127%).
Fig. 3. Correlation between measured whole blood concentrations of
Lp(a) and those calculated with the formula [Lp(a)plasma p (1 2 hemat-
ocrit)]. Fifteen hemodialysis patients and 11 control subjects were in-
cluded in this analysis. r 5 0.99; P , 0.001.
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more decisive for the pathophysiological processes related
to lipoproteins. Since the vessel wall is in contact with
whole blood and not with the isolated subsystems of plasma
or cells, it is highly conceivable that the concentrations
measured in whole blood are more informative or predic-
tive for the atherogenic potential of lipoproteins than those
measured in plasma.
It was not the intention of this study to investigate
whether the concentration of Lp(a) is regulated by the
plasma or the whole blood concentration, which would
definitely require the use of other methods. Our study
questioned the methodological aspects of lipoprotein mea-
surements and the consequences of such measurements in
clinical and epidemiological investigations, especially when
examining patients with renal disease.
Our findings demonstrate that there is a clear need to
consider hematocrit values in case-control studies investi-
gating patients with renal disease who often have markedly
reduced hematocrit levels. Otherwise, these studies may
markedly underestimate Lp(a). We emphasize that Lp(a)
serves only as an example for a general problem in clinical
chemistry. The results can be extrapolated at least to all
parameters like lipoproteins or apolipoproteins, which are
distributed only in the plasma or serum fraction after
centrifugation. We believe that reports on decreased or
normal total and LDL cholesterol levels, decreased HDL
cholesterol levels [15], or increased apolipoprotein A-IV
concentrations [7] in hemodialysis patients should be inter-
preted in the light of these observations.
In consequence, longitudinal studies measuring concen-
trations before and after a treatment (illness) must control
for possible changes of hematocrit levels caused by the
treatment (illness). This is especially true for surgical
interventions where the patient may have homeostatical
changes or when using drugs that affect the hematocrit
directly, where hematocrit must be considered to be a
confounding variable when lipoproteins are measured lon-
gitudinally in plasma. However, even previous studies
investigating drugs that intentionally affect the hematocrit,
such as erythropoietin, did not consider the influence of
hematocrit changes on the measured lipoprotein concen-
trations in plasma [16]. The same principle can at least
partially explain the 20% increase of proteins and lipopro-
teins during a hemodialysis session [17]. By therapeutic
elimination of the volume overload these plasma compo-
nents become more concentrated, which is accompanied by
a similar increase in hemoglobin.
Finally, it should be pointed out that the hematocrit
measurement can be ignored in case-control studies where
there are no differences in hematocrit levels between
groups or in longitudinal studies when no changes of
hematocrit occur.
Our findings are supported by the observation that low
molecular weight anticoagulants, such as fluoride, citrate or
oxalate, exert osmotic effects that shift rather large
amounts of water from erythrocytes to plasma [18]. This
results in an artificially-low hematocrit level and dilutes
plasma constituents such as cholesterol [19]. Furthermore,
posture is an in vivo observation that influences plasma
concentrations: when a standing subject sits down or re-
clines, water is redistributed between the vascular and
extravascular compartments. This increases the intravasal
volume and thus dilutes the concentrations of nondiffusible
components, such as cholesterol [20]. These changes in
hematocrit are, however, relatively low in comparison to
those occurring in patients with end-stage renal disease.
In principle, the underlying phenomenon for our obser-
vation has already been described as “volume displacement
effect” [21, 22], which means that deproteinization of
serum eliminates the volume fraction of proteins and
distributes the remaining small molecular weight constitu-
ents in a smaller volume, thus making them more concen-
trated. Our observation demonstrates the same effect in
another system (whole blood) and for a high molecular
weight lipoprotein. Although the principle of this phenom-
enon was already described 60 [21] and 30 years [22] ago,
most clinical studies still do not consider this confounding
effect [16]. On the other hand, for most epidemiological
case-control studies it is uncontested that groups must be
comparable for age and sex; otherwise, age and sex are
handled as confounding variables. Hematocrit, which can
have a very strong influence on the measured parameters, is
ignored, even when there is a well known difference
between the groups, as is true in renal patients.
Our findings clearly demonstrate that hematocrit levels
have a strong influence on the measurement of lipopro-
teins. Therefore, epidemiological studies in patients with
abnormal hematocrit levels or studies investigating longi-
tudinal changes of lipoproteins should consider hematocrit
as confounding variable.
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